Management of Severe Anemia with Melena

Immediate Octreotide Administration

The European Association for the Study of the Liver (EASL) recommends initiating vasoactive drug therapy, such as octreotide, as soon as acute variceal hemorrhage is suspected, with an initial bolus of 50 mcg IV, followed by continuous infusion of 50 mcg/hour, regardless of the severity of anemia 1

The European Association for the Study of the Liver (EASL) suggests transfusing red blood cells with a restrictive strategy, targeting a hemoglobin threshold of 7 g/dL, with a post-transfusion target range of 7-9 g/dL 1
Volume replacement with crystalloids should be initiated immediately alongside octreotide therapy, with consideration of a higher transfusion threshold in patients with massive hemorrhage or underlying conditions 1

Octreotide therapy should be continued for 3-5 days after endoscopic confirmation and treatment of variceal bleeding, to prevent early rebleeding, with a full 5-day course recommended 1

Antibiotic prophylaxis, such as ceftriaxone or norfloxacin, should be initiated immediately as part of the standard algorithm for acute GI bleeding with suspected portal hypertension 1
Upper endoscopy should be performed within 12 hours of admission to confirm the bleeding source and provide endoscopic band ligation if variceal hemorrhage is confirmed, with consideration of erythromycin 250 mg IV to improve visibility 1

The American Heart Association and European Society of Cardiology suggest considering a higher transfusion threshold in patients with underlying cardiac disease or elderly patients, as severe anemia with hemodynamic instability may require more aggressive transfusion 2
The combination of endoscopic therapy and vasoactive drugs is more effective than either alone and is considered the standard of care, with up to 30% of cirrhotic patients bleeding from non-variceal causes, emphasizing the importance of endoscopic confirmation 1